Insulet Corporation (PODD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$167.53
Price Target
$339.00
Target Range
$220.00 — $435.00
Analyst Rating
Buy
Forward P/E26.4x
Trailing P/E48.1x
Forward PEG0.25
Implied Growth+82.4%
Median Target$330.00
Analyst Spread63.4%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$220
+31.3%
Consensus
$339
+102.4%
Bull Case
$435
+159.7%
PODD Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Insulet Corporation (PODD) has a Wall Street consensus price target of $339.00, based on estimates from 50 covering analysts. With the stock currently trading at $167.53, this represents a potential upside of +102.4%. The company has a market capitalization of $11.79B.
Analyst price targets range from a low of $220.00 to a high of $435.00, representing a 63% spread in expectations. The median target of $330.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 35 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 3 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PODD trades at a trailing P/E of 48.1x and forward P/E of 26.4x. The forward PEG ratio of 0.25 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +82.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+38.0%
Avg Forward P/E15.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 DXCMDexCom, Inc. | $23.0B | $59.48 | $80.88 | +36.0% | Buy | 23.9x | 52 |
 TNDMTandem Diabetes Care, Inc. | $1.3B | $19.42 | $31.62 | +62.8% | Buy | — | 39 |
 NVCRNovoCure Limited | $1.8B | $15.88 | $33.50 | +111.0% | Buy | — | 15 |
 ITGRInteger Holdings Corporation | $3.0B | $85.85 | $98.00 | +14.2% | Buy | 13.2x | 14 |
 ABTAbbott Laboratories | $151.6B | $87.17 | $128.71 | +47.6% | Buy | 15.9x | 41 |
 MDTMedtronic plc | $99.7B | $77.79 | $109.50 | +40.8% | Buy | 14.1x | 49 |
 BDXBecton, Dickinson and Company | $52.2B | $144.17 | $172.85 | +19.9% | Buy | 11.5x | 33 |
 NVONovo Nordisk A/S | $151.4B | $44.89 | $47.00 | +4.7% | Buy | 2.1x | 39 |
 LLYEli Lilly and Company | $933.7B | $988.19 | $1258.47 | +27.4% | Buy | 28.6x | 45 |
 SNYSanofi | $104.7B | $43.36 | $50.00 | +15.3% | Buy | 10.3x | 27 |
Upside Potential Comparison
NVCRTNDMABTMDTDXCMLLYBDXSNYFull PODD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PODD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PODD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PODD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPODD — Frequently Asked Questions
Quick answers to the most common questions about buying PODD stock.
What is the PODD stock price target for 2026?
The consensus Wall Street price target for PODD is $339, representing 102.4% upside from the current price of $167.53. With 50 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PODD a buy, sell, or hold?
PODD has a consensus rating of "Buy" based on 50 Wall Street analysts. The rating breakdown is predominantly bullish, with 35 Buy/Strong Buy ratings. The consensus 12-month price target of $339 implies 102.4% upside from current levels.
Is PODD stock overvalued or undervalued?
PODD trades at a forward P/E of 26.3549x, representing a moderate valuation. With analysts targeting $339 (102.4% implied move), the stock appears reasonably valued with upside.
How high can PODD stock go?
The most bullish Wall Street analyst has a price target of $435 for PODD, while the most conservative target is $220. The consensus of $339 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PODD stock?
PODD is heavily covered by Wall Street, with 50 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 35 have Buy ratings, 12 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PODD stock forecast?
The 12-month PODD stock forecast based on 50 Wall Street analysts shows a consensus price target of $339, with estimates ranging from $220 (bear case) to $435 (bull case). The median consensus rating is "Buy".
What is PODD's forward P/E ratio?
PODD trades at a forward P/E ratio of 26.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 48.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PODD stock?
Wall Street analysts are very optimistic on PODD, with a "Buy" consensus rating and $339 price target (102.4% upside). 35 of 50 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PODD price targets vary so much?
PODD analyst price targets range from $220 to $435, a 63% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $339 consensus represents the middle ground.